Establishment Labs [ESTA] vs Conmed [CNMD] Detailed Stock Comparison
Establishment Labs
NASDAQ
Loading...
Conmed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Establishment Labs wins in 5 metrics, Conmed wins in 13 metrics, with 0 ties. Conmed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Establishment Labs | Conmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -14.55 | 14.99 | Establishment Labs |
| Price-to-Book Ratio | 50.89 | 1.64 | Conmed |
| Debt-to-Equity Ratio | 993.34 | 87.93 | Conmed |
| PEG Ratio | 1.80 | -0.52 | Conmed |
| EV/EBITDA | -24.62 | 11.37 | Establishment Labs |
| Profit Margin (TTM) | -49.89% | 8.31% | Conmed |
| Operating Margin (TTM) | -27.50% | 10.62% | Conmed |
| EBITDA Margin (TTM) | N/A | 10.62% | N/A |
| Return on Equity | -261.18% | 11.69% | Conmed |
| Return on Assets (TTM) | -12.78% | 4.03% | Conmed |
| Free Cash Flow (TTM) | $-74.08M | $153.88M | Conmed |
| Dividend Yield | N/A | 1.15% | N/A |
| 1-Year Return | -4.40% | -22.43% | Establishment Labs |
| Price-to-Sales Ratio (TTM) | 6.53 | 1.24 | Conmed |
| Enterprise Value | $1.33B | $2.50B | Conmed |
| EV/Revenue Ratio | 7.50 | 1.89 | Conmed |
| Gross Profit Margin (TTM) | 68.76% | 55.01% | Establishment Labs |
| Revenue per Share (TTM) | $6 | $43 | Conmed |
| Earnings per Share (Diluted) | $-3.08 | $3.54 | Conmed |
| Beta (Stock Volatility) | 0.83 | 1.17 | Establishment Labs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Establishment Labs vs Conmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Establishment Labs | 9.10% | 13.88% | 0.39% | 18.43% | 23.94% | -3.62% |
| Conmed | 5.16% | 5.06% | 16.20% | -0.45% | -9.94% | -17.13% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Establishment Labs | -4.40% | -33.19% | 147.95% | 65.37% | 65.37% | 65.37% |
| Conmed | -22.43% | -39.27% | -35.67% | 3.79% | 192.05% | 100.61% |
Performance & Financial Health Analysis: Establishment Labs vs Conmed
| Metric | ESTA | CNMD |
|---|---|---|
| Market Information | ||
| Market Cap | $1.16B | $1.64B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 543,540 | 441,677 |
| 90 Day Avg. Volume | 416,250 | 535,656 |
| Last Close | $43.64 | $55.81 |
| 52 Week Range | $26.56 - $50.85 | $46.00 - $78.19 |
| % from 52W High | -14.18% | -28.62% |
| All-Time High | $93.80 (Apr 18, 2022) | $159.11 (Nov 01, 2021) |
| % from All-Time High | -53.48% | -64.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.03% |
| Quarterly Earnings Growth | 0.16% | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | 0.08% |
| Operating Margin (TTM) | -0.28% | 0.11% |
| Return on Equity (TTM) | -2.61% | 0.12% |
| Debt to Equity (MRQ) | 993.34 | 87.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.79 | $32.41 |
| Cash per Share (MRQ) | $1.89 | $1.10 |
| Operating Cash Flow (TTM) | $-72,688,000 | $165.21M |
| Levered Free Cash Flow (TTM) | $-39,815,124 | $163.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.15% |
| Last 12-Month Dividend | N/A | $0.60 |
Valuation & Enterprise Metrics Analysis: Establishment Labs vs Conmed
| Metric | ESTA | CNMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -14.55 | 14.99 |
| Forward P/E | -24.24 | 10.96 |
| PEG Ratio | 1.80 | -0.52 |
| Price to Sales (TTM) | 6.53 | 1.24 |
| Price to Book (MRQ) | 50.89 | 1.64 |
| Market Capitalization | ||
| Market Capitalization | $1.16B | $1.64B |
| Enterprise Value | $1.33B | $2.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.50 | 1.89 |
| Enterprise to EBITDA | -24.62 | 11.37 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 1.17 |
| Book Value per Share (MRQ) | $0.79 | $32.41 |
Financial Statements Comparison: Establishment Labs vs Conmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ESTA | CNMD |
|---|---|---|
| Revenue/Sales | $51.30M | $321.26M |
| Cost of Goods Sold | $16.03M | $143.50M |
| Gross Profit | $35.27M | $177.75M |
| Research & Development | $5.20M | $12.95M |
| Operating Income (EBIT) | $-14.11M | $15.96M |
| EBITDA | $-7.04M | $34.21M |
| Pre-Tax Income | $-15.59M | $7.67M |
| Income Tax | $1.00M | $1.64M |
| Net Income (Profit) | $-16.59M | $6.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ESTA | CNMD |
|---|---|---|
| Cash & Equivalents | $69.18M | $35.49M |
| Total Current Assets | $231.70M | $639.00M |
| Total Current Liabilities | $69.04M | $283.15M |
| Long-Term Debt | $224.14M | $891.44M |
| Total Shareholders Equity | $38.55M | $977.64M |
| Retained Earnings | $-465.40M | $560.13M |
| Property, Plant & Equipment | $5.19M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ESTA | CNMD |
|---|---|---|
| Operating Cash Flow | $-24.24M | $49.72M |
| Capital Expenditures | $-753,000 | $-3.78M |
| Free Cash Flow | $-21.75M | $37.76M |
| Debt Repayment | N/A | $-180.59M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ESTA | CNMD |
|---|---|---|
| Shares Short | 4.76M | 2.10M |
| Short Ratio | 14.57 | 4.31 |
| Short % of Float | 0.24% | 0.09% |
| Average Daily Volume (10 Day) | 543,540 | 441,677 |
| Average Daily Volume (90 Day) | 416,250 | 535,656 |
| Shares Outstanding | 28.79M | 30.90M |
| Float Shares | 16.95M | 30.68M |
| % Held by Insiders | 0.11% | 0.01% |
| % Held by Institutions | 1.05% | 1.15% |
Dividend Analysis & Yield Comparison: Establishment Labs vs Conmed
| Metric | ESTA | CNMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.60 |
| Last 12-Month Dividend Yield | N/A | 1.15% |
| 3-Year Avg Annual Dividend | N/A | $0.73 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $2.20 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |